LCNDG Rapid Review: Pazopanib for 3rd line metastatic non adipocytic soft tissue sarcoma

Source: London Cancer New Drugs Group Area: Evidence > Drug Specific Reviews Pazopanib has been compared with best supportive care in the PALETTE study, therefore the place in therapy of pazopanib is yet to be determined. However given that there are very limited treatment options and that most of these are given by injection, an oral targeted therapy could provide potential benefits to patients and cancer services.   How clinically significant is a statistically significant improvement in PFS but not OS in advanced STS?   The study was not adequately powered to detect a three month benefit for OS. An adequately powered trial would need more than 750 patients which was not deemed feasible. Furthermore, post-progression therapy was administered and considered variably therefore it is not known what impact this may have had on OS in both groups.   The efficacy of pazopanib has not been demonstrated for patients with adipocytic STS or GIST.   Study patients had performance status of 0 or 1 so the efficacy and ...
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news